🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 14 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 06/09/2019 | 180,35 | 182,15 | 179,33 | 181,33 | +0,82% | 1,56% | 979.400 |
| 05/09/2019 | 178,18 | 180,05 | 177,02 | 179,86 | +1,71% | 1,70% | 868.700 |
| 04/09/2019 | 179,73 | 179,75 | 173,56 | 176,83 | -1,05% | 3,44% | 1.003.300 |
| 03/09/2019 | 180,55 | 181,57 | 177,58 | 178,70 | -0,73% | 2,21% | 1.030.100 |
| 30/08/2019 | 180,26 | 181,20 | 178,76 | 180,02 | +0,58% | 1,35% | 892.900 |
| 29/08/2019 | 179,30 | 180,50 | 178,14 | 178,98 | +0,36% | 1,32% | 680.300 |
| 28/08/2019 | 177,47 | 180,71 | 170,54 | 178,34 | +0,05% | 5,73% | 1.680.200 |
| 27/08/2019 | 181,99 | 182,92 | 177,27 | 178,25 | -1,32% | 3,10% | 940.100 |
| 26/08/2019 | 180,82 | 182,38 | 179,56 | 180,64 | +0,26% | 1,56% | 829.500 |
| 23/08/2019 | 184,36 | 186,78 | 179,24 | 180,18 | -2,19% | 4,09% | 1.198.700 |
| 22/08/2019 | 186,76 | 187,62 | 181,48 | 184,21 | -1,17% | 3,29% | 1.026.800 |
| 21/08/2019 | 185,86 | 187,30 | 184,60 | 186,40 | +1,46% | 1,45% | 575.500 |
| 20/08/2019 | 187,04 | 188,44 | 182,90 | 183,72 | -1,80% | 2,96% | 1.001.300 |
| 19/08/2019 | 186,24 | 187,71 | 185,88 | 187,09 | +1,16% | 0,98% | 963.200 |
| 16/08/2019 | 183,08 | 185,75 | 180,84 | 184,94 | +2,11% | 2,68% | 1.304.200 |
| 15/08/2019 | 180,01 | 182,04 | 178,37 | 181,12 | +0,89% | 2,04% | 823.100 |
| 14/08/2019 | 181,77 | 183,57 | 178,85 | 179,53 | -2,38% | 2,60% | 1.405.800 |
| 13/08/2019 | 178,36 | 185,54 | 178,04 | 183,91 | +2,26% | 4,20% | 1.246.100 |
| 12/08/2019 | 182,06 | 183,14 | 179,12 | 179,84 | -1,72% | 2,21% | 1.160.900 |
| 09/08/2019 | 182,94 | 184,07 | 179,39 | 182,98 | +0,02% | 2,56% | 1.275.800 |
| 08/08/2019 | 175,59 | 183,11 | 175,59 | 182,94 | +4,15% | 4,28% | 1.641.700 |
| 07/08/2019 | 175,11 | 176,47 | 172,48 | 175,65 | -0,73% | 2,28% | 941.000 |
| 06/08/2019 | 174,23 | 177,05 | 173,64 | 176,94 | +0,79% | 1,96% | 1.287.600 |
| 05/08/2019 | 176,44 | 177,14 | 173,92 | 175,56 | -1,59% | 1,82% | 1.709.400 |
| 02/08/2019 | 177,78 | 180,97 | 177,06 | 178,39 | -0,50% | 2,20% | 1.814.900 |
| 01/08/2019 | 173,42 | 181,30 | 170,13 | 179,29 | +7,60% | 6,44% | 3.130.300 |
| 31/07/2019 | 168,79 | 170,21 | 165,66 | 166,62 | -1,72% | 2,70% | 1.460.400 |
| 30/07/2019 | 165,74 | 171,10 | 165,52 | 169,54 | +1,99% | 3,37% | 2.339.000 |
| 29/07/2019 | 167,21 | 167,51 | 165,27 | 166,23 | -0,36% | 1,34% | 1.366.600 |
| 26/07/2019 | 170,18 | 171,13 | 165,85 | 166,83 | -1,61% | 3,10% | 1.640.900 |